Company Profile

Company Overview & History

Company Overview

Company Name BrightPath Biotherapeutics Co., Ltd.
Location

Corporate Headquarters

Kojimachi Central Building 7F, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo MAP

Kawasaki Research Laboratories
Cell Technology Laboratories

Life Innovation Center 412, 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa  MAP
Established May 8, 2003
Capital Stock 6,700million yen(as of March 31, 2022)
Number of Employees 38people(as of March 31, 2022)

History

May 2003 Established at Kurume, Fukuoka Prefecture
January 2006 Started a phase I clinical trial of ITK-1 for castration-resistant prostate cancer
November 2011 Reached an out-license agreement on ITK-1 with FUJIFILM Corporation
June 2013 Started a phase III clinical trial of ITK-1 for castration-resistant prostate cancer
June 2015 Interim analysis of the phase III study trial of ITK-1 in CRPC completed & the study continued as planned
October 2015 Started a phase I clinical trial of GRN-1201 for melanoma in the US

Listed on the Tokyo Stock Exchange (code:4594)
August 2016 Opened Kawasaki Research Laboratory at Kawasaki, Kanagawa prefecture
January 2017 Started a phase II clinical trial of GRN-1201 in combination with an immune checkpoint antibody in patients with non-small cell lung cancer in the US
July 2017 Changed company name from GreenPeptide to BrightPath Biotherapeutics
April 2018 Joined iPS-NKT development project promoted by RIKEN
May 2018 Opened the keys-code of the phase III double-blind placebo-controlled study for ITK-1
May 2019 Terminated development of ITK-1
June 2020 Started Phase I clinical trial of iPS-NKT for head and neck cancer
May 2022 Started Phase I clinical trial of HER2-targeted CAR-T cell therapy BP2301
May 2022 Announced the early termination of a phase II clinical trial of GRN-1201 in combination with an immune checkpoint antibody in patients with non-small cell lung cancer in the US
close